Development of discriminative and biorelevant dissolution test method for atorvastatin /fenofibrate combination with appliance of derivative spectrophotometry.

Panikumar Durga Anumolu *, Sunitha Gurrala , Subrahmanyam Chavali Venkata Satya , Santoshi Vani Polisetty, Anjana Ravindran, Radhagayathri Achanta

Gokaraju Rangaraju College of Pharmacy, Department of Pharmaceutical Analysis Osmania University, Hyderabad, Telangana, India

*Address for Correspondence:
Dr Panikumar Durga Anumolu
Gokaraju Rangaraju College of Pharmacy
Department of Pharmaceutical Analysis
Hyderabad
Telangana-500090
India
E-mail: panindrapharma@yahoo.co.in
ABSTRACT

Now a days, market is flooded with combination of drugs in various dosage forms, but lack of official methods to quantify them. A single dissolution test method for the analysis of combined dosage form is preferred for simplification of quality control testing. If the developed dissolution medium mimics the bio-relevant and discriminating dissolution procedure for drug products with limited drug aqueous solubility is a useful tool for qualitative forecasting of in-vivo behavior of formulations. Dissolution profiles are evaluated for atorvastatin and fenofibrate in capsules, using paddle type USP dissolution apparatus in 900 mL of medium at 50 rpm and 37±0.5 °C. The best medium was 900 mL of 0.5% w/v sodium lauryl sulphate. The cumulative % dissolution was more than 85% within 45 min time for marketed tablets. The proposed dissolution test conditions have the discriminative power, dissimilarity factor \((f_1)\) are low (12-16%) and similarity \((f_2)\) factor values were also low (45-48%). Hence the use of 0.5% w/v sodium lauryl sulphate solution is justified. The dissolution method was validated (% RSD<2). To quantify both drugs simultaneously, a second derivative spectrophotometric was established \((\lambda_{max} \, 281 \, nm \, and \, 296 \, nm, \, respectively, \, for \, atorvastatin \, and \, fenofibrate)\) in acetate buffer, pH 2.8 solution.

Key words: Derivative spectrophotometry/quantification simultaneously, Atorvastatin/Fenofibrate combined dosage form, Bio relevant/discriminative dissolution method.
INTRODUCTION

Dissolution is considered as one of the most routinely performed quality control tests on dosage forms to ensure uniformity and reproducibility of production batches. Process parameters and ingredients are optimized during product development\(^1\)-\(^3\), whether changes made in the formulations or their manufacturing processes are likely to affect the performance in the clinic or not are decided using dissolution methods\(^4\). An immediate release dosage form is designed to deliver the drug rapidly into systemic circulation. Hence, the dissolution may become the rate limiting step for its absorption. The absorption of a drug substance may vary by diverse parameters like its solubility and permeability in the conditions associated with the gastrointestinal (GI) tract after oral administration\(^5\)-\(^7\). Keeping all these points into consideration, there is a need to put more research efforts on developing in vitro GI fluids that mimics the in-vivo conditions. The discriminative dissolution method has ability to differentiate the dissolution profiles between manufacturer process variations and product composition variations\(^8\)-\(^10\).

Fenofibrate, chemically known as Isopropyl 2-[4-(4-chlorobenzoyl)2-phenoxy] methyl propanoate, is a fibric acid derivative with lipid regulating properties striving its therapeutic effects through activation of peroxisome proliferator activated receptor α (PPARα) (Figure-1A). Atorvastatin Calcium chemically \([R-(R',R'')]-2-(4-Fluorophenyl)-\beta,\delta\text{-dihydroxy-5-(1-methylethyl)-3-phenyl \[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid,}\ is a HMG-CoA reductase inhibitor with hypolipidemic properties\(^11\)-\(^12\)(Figure-1B). The combined dosage form of fenofibrate and atorvastatin is therapeutically used for hyperlipidemic patients. Fixed dose combination of drugs has been a challenge; if possible a single dissolution method is preferred to simplify quality control testing procedures\(^13\)-\(^15\). Few analytical methods were reported for simultaneous quantification of atorvastatin calcium and Fenofibrate by HPLC and spectrophotometric method\(^16\)-\(^19\). The facility of derivative spectroscopy may be used with minimum error for the quantification of one analyte\(^20\),\(^21\). Overlaid zero-order spectra exhibited similar nature and overlapping for atorvastatin calcium with fenofibrate denotes development of the derivative graphical method. To the best of our knowledge, only one first and second derivative spectrophotometric method reported for simultaneous quantification of ATV and FEN in methanol as solvent, but methanol is environmental toxic and expensive than aqueous buffers and one
wavelength is 245 nm, which is normally originated by the benzenoid ring system. Since several compounds may contain benzene rings, it is always better to avoid 245 nm and select a wavelength away from 245 nm. Literature data signify the need of simple, economic, eco friendly and specific analytical method for simultaneous quantification of ATV and FEN combination in tablets and dissolution samples. The development of a single dissolution method is practically challenging due to their low water solubility for combination of atorvastatin and fenofibrate. Keeping these points into consideration, an attempt is made to develop and validate the single dissolution test for simultaneous quantification with application of simple derivative spectrophotometric technique.

MATERIALS AND METHODS

Materials

Atorvastatin and fenofibrate were obtained as gift samples from Dr. Reddy’s, Laboratories limited, Hyderabad, India. Methanol, hydrochloric acid, ortho-phosphoric acid, potassium di hydrogen orthophosphate, sodium hydroxide, sodium chloride and sodium acetate were purchased from Sd Fine-Chem limited, Mumbai; sodium lauryl sulfate (SLS), tween 80, cetrimide, lecithin and sodium taurocholate were purchased from Himedia Ltd, Mumbai, India. Double distilled water was used throughout the study. Atorvastatin and fenofibrate combination tablet formulations – Atocor (Dr. Reddy’s, Laboratories Pvt. Ltd) and Fibator (Sun Pharma, Sikkim) were obtained from local market.

Instrumentation

Double beam 1800 UV-Visible spectrophotometer (Shimadzu, Japan), dissolution apparatus (Electro lab TDT-08L), analytical balance (Shimadzu AUX 220, Japan), tablet compression machine (Lab press- CIP machineries, Ahmedabad, India), hardness tester (Secor, Hyderabad, India) pH meter (Elico, Hyderabad) and ultrasonic cleaner were used for the study (Calibration of instruments were done according to standard procedure).

Analytical method

First-order-derivative overlaid spectra of atorvastatin calcium and fenofibrate denotes that there was no zero crossing point for atorvastatin calcium for quantification of fenofibrate (Figure 2). Hence first derivative spectrum was not suitable for
simultaneous estimation and this problem was minimized by second-order-derivative method, which permitted to select the suitable wavelengths that make the quantification possible with zero crossing, where fenofibrate zero absorbance at 281 nm, while atorvastatin calcium gave the significant derivative response likewise atorvastatin gave zero absorbance at 296 nm, while fenofibrate gave the significant derivative response. Therefore, 281 nm and 296 nm were selected for estimation of atorvastatin calcium and fenofibrate, respectively.

**Dissolution test conditions**

The log P values of atorvastatin calcium and fenofibrate were 6.36 and 5.28, respectively indicating low water solubility so the development of a single dissolution method for this combination is challenge and a single in vitro dissolution studies were not reported for this combination along these lines, an attempt is made to develop and validate a single dissolution test for atorvastatin calcium and fenofibrate in combined tablets.

Evaluated the dissolution profiles of atorvastatin calcium (10 mg) and fenofibrate (145 mg) bulk drug-filled capsules in 900 mL of seven buffers of distinct pH (1.2/2.8/3.6/4.7/5.6/6.8 and 7.4), biorelevant media such as [SGF (pH 1.2), SIF (pH 7.5), FaSSIF (pH 6.5), FeSSIF (pH 5.0), modified fasted state (pH 6.5) and fed state (pH 5.0) simulated intestinal fluids)] and three different surfactants and at 2 different concentrations at 50 rpm using type 2, USP dissolution apparatus and samples were withdrawn for 60 min, replaced with same volume of fresh medium. Samples withdrawn were evaluated with regression equation of proposed analytical technique for quantification of dissolved-drug followed by plot counter to time. A combination of these media was utilized for identifying the optimized dissolution medium, in which highest drug release, stability and sink conditions were obtained, was chosen as the in vitro dissolution medium.

**Discriminatory power of the dissolution method**

Dissolution method ability to discriminate was ascertained by the tablets punched under distinct conditions, such as; discrete manufacturing process (hardness of 5.0 kg/cm² and 8.0 kg/cm²) and discrete product composition (with/without disintegrant). Scrutinizing the dissolution-profiles in test conditions followed by data was estimated with factors of comparison (f₁ and f₂).
Stability determination

Sample solutions withdrawn for the optimized dissolution medium were analyzed at 0 time, consonantly samples were kept for 24 hours and 48 hours and analyzed by proposed method.

Validation of the dissolution method

The validation of dissolution method is required to ensure that a proposed dissolution method is scientifically and experimentally sound, obtaining the results of specificity, linearity, accuracy and precision as per standard guidelines.

The method specificity was assessed by comparing the spectra obtained from the commercial formulations and the synthetic mixture from standard solutions by preparing similar dose ratio of synthetic and tablet dosage form. Then analytical method was applied in order to check if any component of the formulation could generate a response or an absorption wavelength similar to the drugs.

Linearity was determined by standard concentrations of atorvastatin (2-12 µg/mL) and fenofibrate (1-35 µg/mL) were quantified with second derivative spectrophotometric technique, then absorbance was recorded and calibration curve was constructed by plotting the analyte response versus the drug concentrations.

Intra-day and inter-day precision studies were evaluated as per ICH guidelines, in which six tablets were subjecting to the dissolution test conditions, on the same day (intra-day precision) and for three consecutive days (inter-day precision), then % RSD was calculated.

Accuracy studies were conducted using standard addition method where the known amount of drugs at 80, 100 and 120% of the formal assay of atorvastatin and fenofibrate to the placebo sample in the dissolution medium, further subjected to contemplated method; then percentage recovery and relative standard deviation (% RSD) were computed for each concentration.

RESULTS AND DISCUSSION

Development of dissolution method

The selection of a dissolution test method was based on dissolution profiles of atorvastatin (10 mg) and fenofibrate (145 mg) bulk drug filled capsules using a USP type 2 apparatus at a paddle speed of 50 rpm and selection of a dissolution medium.
to adequate solubility and stability of both atorvastatin calcium and fenofibrate was demand for this dissolution method. The log P values of atorvastatin calcium and fenofibrate respectively were 6.36 and 5.28, denoting low water solubility. Several compendia dissolution media were screened; these include various buffer media (pH 1.2 to 7.4), surfactant media and several bio-relevant media, However, the results showed that the dissolution rate of atorvastatin was found to be maximum in weak acidic buffers because of the specific interaction but fenofibrate dissolution rate was less than 2% in all buffers, indicating that fenofibrate dissolution was independent of pH due to absence of ionizable groups (Table I). Both drugs were showed higher dissolution in 0.5% w/v sodium lauryl sulphate medium than other dissolution media. Dissolution medium with low concentration of sodium lauryl sulphate may resemble gastric environment of our body, and hence this medium is useful for correlating in-vitro dissolution behavior of atorvastatin and fenofibrate combined dosage form with their in-vivo performance. This medium can also be a useful quality control tool and the selected dissolution test conditions are: USP apparatus 2 at paddle speed 50 rpm in a medium of 0.5% w/v sodium lauryl sulphate. Therefore, dissolution studies were performed for commercial tablets (Atocor and Fibator) in optimised dissolution test conditions.

*In-vitro dissolution profiles of commercial tablets*

Dissolution studies on Atocor and Fibator tablets were enforced under the optimised dissolution test medium of 0.5% w/v sodium lauryl sulphate, by using USP type 2 apparatus at paddle speed of 50 rpm at temperature 37 ± 0.5 °C and these results are obtained in Figure 3 and 4, indicated that about 85% of both atorvastatin and fenofibrate were released in 45 min from the two brands. In fact, fenofibrate exhibited only 50% dissolution in 60 min (Table I). On the other hand, tablets exhibited 85% dissolution in 45 min; it means that the inactive ingredients in the tablets also supported the dissolution. Such a factor should also be kept in mind, while optimising the dissolution conditions. Atorvastatin components of the tablet formulation exhibited 88% dissolution in 45 min, whereas the pure drug exhibited 92% dissolution in 45 min in same medium. Thus the proposed dissolution medium satisfactorily reproduced the dissolution characteristics of atorvastatin and fenofibrate with initial lag time of 5 min for drug dissolution but lag time is more pronounced in case of fenofibrate. This trend was familiar from the chemical structure of fenofibrate.
(no functional groups responsible for ionization). Further both drugs are hydrophobic as indicated by the log P values, 6.36 and 5.28, respectively for atorvastatin and fenofibrate. From 5 min to 60 min periods, the dissolution behavior is gradual and linear, which again reflected the hydrophobic nature of the drugs.

**Discriminatory power of the dissolution method**

Discriminatory power of the dissolution method was determined by manufacturing the tablets under different conditions and studying the behavior of those products in the proposed dissolution method. The effect of tablet hardness (5 kg/cm² vs 8 kg/cm²) and disintegrant (with vs without) were shown in Figure 5 followed by data of dissolution was compute with the factors of comparison using 6 points; among these, one point was found to specify the drug release more than 85% (Table II). These results confirmed that the dissolution test procedure has ability to discriminate for distinct composition and process, based on these results, 0.5% w/v sodium lauryl sulphate medium has discriminating power.

**Stability determination of atorvastatin and fenofibrate in dissolution medium**

The stability of drugs in dissolution medium at different time periods was calculated in order to demonstrate the integrity of the drugs and obtained in Table III, notified that both drugs were stable under dissolution test conditions. The change in drug content was not assessed and likewise no evidence of degradation denotes that the solutions were stable for more than 48 h.

**Dissolution method validation**

**Linearity**

The linearity was assessed by the regression equation of calibration curve method. The responses for atorvastatin at 281 nm were found to be linear in the concentration range of 2-12 μg/mL, with a correlation co-efficient ($R^2$) value of 0.9971 likewise the responses for fenofibrate at 296 nm were linear in the concentration range of 1-35 μg/mL, with a correlation coefficient ($R^2$) value of 0.998. The results indicate a good linear relationship between derivative response and concentrations at 281 nm and 296 nm. (Figure 6)

**Specificity**
Derivative spectrum attained from the commercial formulation solution was correlated with the spectrum of synthetic mixture of standard solutions (atorvastatin and fenofibrate). The spectra of commercial formulation and synthetic mixture were superimposed; denotes no interference from excipients with derivative response of either of drugs (atorvastatin and fenofibrate) at their respective analytical wavelengths 281 nm and 296 nm (Figure 7), hence the method was found to be specific.

**Precision**

The precision evaluation data for the dissolution studies was obtained in Table IV, denoted that percent relative standard deviation values for intra-day and inter-day precision studies were found to be less than 2 and there was no significant differences, which indicates the proposed method was reproducible and precise.

**Accuracy**

The accuracy assessment data for the dissolution studies was obtained in Table V, denoted that percent recovery was from 96 - 106% and percent relative standard values were less than 2, showed that an agreement between the standard values and ascertained values signifies dissolution method was accurate.

**CONCLUSION**

The present investigation was undertaken with the objective to develop and validate of single test method for the dissolution evaluation of atorvastatin calcium and fenofibrate simultaneously. The best conditions were optimised for dissolution testing for atorvastatin and fenofibrate are: 900 mL of 0.5% w/v sodium lauryl sulphate, using paddle type USP dissolution apparatus, stirring speed of 50 rpm, a temperature of 37±0.5 °C and collection time of 60 min. The proposed dissolution test conditions have the discriminative power, substantiated the usefulness of this biorelevant medium for the two drugs and the dissolution method was validated (% RSD<2). The developed dissolution method can be fruitfully employed as quality control tool as well as research tool.

**ACKNOWLEDGMENTS**
The authors are thankful to the management of Gokaraju Rangaraju College of Pharmacy for providing necessary facilities and infrastructure to carry out this research work.

REFERENCES


**TABLE 1.** Screening study results for ATV (10 mg) and FEN (145 mg) bulk drug using a USP type II apparatus at 50 rpm, temperature 37°C ± 0.5 for 60 min.

<table>
<thead>
<tr>
<th>Dissolution media</th>
<th>% Drug release</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ATV</td>
<td>FEN</td>
</tr>
<tr>
<td>Mean ± SD (n = 12)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.1 N Hydrochloric acid</td>
<td>18.40 ± 0.09</td>
<td>1.16 ± 0.07</td>
</tr>
<tr>
<td>Acetate buffer, pH 2.8</td>
<td>29.56 ± 0.04</td>
<td>1.47 ± 0.07</td>
</tr>
<tr>
<td>Acetate buffer, pH 3.6</td>
<td>41.40 ± 1.66</td>
<td>1.14 ± 0.08</td>
</tr>
<tr>
<td>Acetate buffer pH 4.7</td>
<td>48.43 ± 2.16</td>
<td>1.12 ± 0.10</td>
</tr>
<tr>
<td>Phosphate buffer, pH 5.6</td>
<td>92.45 ± 2.96</td>
<td>0.93 ± 0.04</td>
</tr>
<tr>
<td>Phosphate buffer, pH 6.8</td>
<td>95.45 ± 4.18</td>
<td>1.02 ± 0.02</td>
</tr>
<tr>
<td>Phosphate buffer, pH 7.4</td>
<td>86.59 ± 1.40</td>
<td>1.04 ± 0.05</td>
</tr>
<tr>
<td>SGF (simulated gastric fluid without enzyme)</td>
<td>50.28 ± 3.71</td>
<td>1.04 ± 0.06</td>
</tr>
<tr>
<td>SIF (simulated intestinal fluid)</td>
<td>87.59 ± 2.40</td>
<td>1.94 ± 0.05</td>
</tr>
<tr>
<td>BFaSSIF (Blank fasted state simulated intestinal fluid)</td>
<td>95.88 ± 1.76</td>
<td>1.20 ± 0.06</td>
</tr>
<tr>
<td>BFeSSIF (Blank fed state simulated intestinal fluid)</td>
<td>92.46 ± 2.45</td>
<td>1.33 ± 0.08</td>
</tr>
<tr>
<td>M FaSSIF (Modified fasted state simulated intestinal fluid)</td>
<td>98.00 ± 1.19</td>
<td>5.33 ± 0.75</td>
</tr>
<tr>
<td>MFeSSIF (Modified fed state simulated intestinal fluid)</td>
<td>92.45 ± 0.60</td>
<td>4.15 ± 0.21</td>
</tr>
<tr>
<td>Cetrimide, 0.25% w/v</td>
<td>98.33 ± 5.41</td>
<td>7.08 ± 0.07</td>
</tr>
<tr>
<td>SLS 0.25% w/v</td>
<td>94.00 ± 5.27</td>
<td>30.54 ± 0.54</td>
</tr>
<tr>
<td>Tween 80 0.25% v/v</td>
<td>40.87 ± 0.02</td>
<td>2.36 ± 0.17</td>
</tr>
<tr>
<td>SLS 0.5% w/v</td>
<td>95.42 ± 2.56</td>
<td>50.54 ± 0.53</td>
</tr>
</tbody>
</table>
Table 2. Dissimilarity factor ($f_1$) and similarity factor ($f_2$) for dissolution profiles of tablets.

<table>
<thead>
<tr>
<th>Name of the drug</th>
<th>Tablets with hardness of 5 kg/cm² Vs8 kg/cm²</th>
<th>Tablets with disintegrant Vs no disintegrant</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$f_1$ value</td>
<td>$f_2$ value</td>
</tr>
<tr>
<td>Atorvastatin</td>
<td>16</td>
<td>45.44</td>
</tr>
<tr>
<td>Fenofibrate</td>
<td>17</td>
<td>48.30</td>
</tr>
<tr>
<td>Analyte</td>
<td>% Amount of drug found (AM ± SD) (n=3)</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td></td>
<td>Initial time</td>
<td>After 24 h</td>
</tr>
<tr>
<td>Atorvastatin</td>
<td>98.24 ± 0.45</td>
<td>99.47 ± 1.24</td>
</tr>
<tr>
<td>Fenofibrate</td>
<td>99.54 ± 0.34</td>
<td>100 ± 0.32</td>
</tr>
</tbody>
</table>

Table 3. Data for stability of atorvastatin and fenofibrate dissolution samples.
Table 4. Precision data of atorvastatin and fenofibrate for the proposed dissolution method

<table>
<thead>
<tr>
<th>Product</th>
<th>Percent amount of atorvastatin</th>
<th>Percent amount of fenofibrate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Intra-day</td>
<td>Inter-day</td>
</tr>
<tr>
<td></td>
<td>Mean±SD*</td>
<td>% RSD</td>
</tr>
<tr>
<td>Atocor</td>
<td>98.86±1.751</td>
<td>1.77</td>
</tr>
<tr>
<td>Fibator</td>
<td>98.49±1.604</td>
<td>1.62</td>
</tr>
</tbody>
</table>